Characterisation of a rat model of mechanical low back pain at an advanced stage using immunohistochemical methods

Abstract

In adult humans, chronic low back pain (LBP) is ranked first for disability of 291 conditions, in the Global Burden of Disease 2010 study. 1 The lifetime risk of suffering non-specific LBP is approximately 84%. 2 Among patients with chronic LBP, approximately 11%-12% are debilitated by this pain condition. 3,4 A major factor contributing to the high morbidity of chronic LBP, is that the underlying pathophysiological mechanisms are largely unknown. Recent research 5 suggests that the pathobiology

Nonopioid analgesics discovery and the Valley of Death: EMA401 from concept to clinical trial

“…To address this issue, multiple research groups, including my own, have invested considerable resources in establishing optimised rodent pain models with back-translated pharmacological data, with the aim to more closely mimic individual chronic pain conditions in humans. 11 Examples include rat models of breast cancer–induced bone pain 95 and prostate cancer–induced bone pain, 39 , 69 rat models of antiretroviral toxic neuropathy (ATN) 53 , 117 and HIV-associated neuropathy, 118 the chronic phase of the monoidoacetate rat model of knee osteoarthritis, 34 a rat model of mechanical low back pain, 73 , 79 a mouse model of chronic low back pain, 62 mechanical nerve injury, 43 an EAE mouse model of central neuropathic pain, 45 , 46 , 48 a genetic model of painful diabetic neuropathy in the type 2 diabetic Zucker diabetic fatty rat, 24 , 77 , 93 as well as models of chemotherapy-induced peripheral neuropathy in both rats 32 , 33 , 60 and mice. 41 , 92 , 110 However, it is too early to draw conclusions on the effectiveness of this strategy to identify novel analgesic drug leads that will be more likely to achieve clinical trial success.…”